Psilocybin for Prolonged Grief Disorder

This open-label, single-arm trial (n=12) will study the effects of a single dose of psilocybin (25mg) on individuals with prolonged grief disorder (PGD).

Conducted by the University of Virginia, this early Phase I trial aims to evaluate the feasibility of using psilocybin-assisted therapy for PGD, a condition marked by intense and persistent grief.

Participants will undergo a preparation session, receive psilocybin in a monitored setting, and then engage in two integration sessions. The study will assess changes in grief symptoms using the Inventory of Complicated Grief (ICG) and will also measure PTSD-related symptoms with the Davidson Trauma Scale (DTS). Additionally, it will explore whether psilocybin induces mystical, spiritual, or insightful experiences that contribute to symptom relief. Follow-up assessments will take place at 1, 3, and 6 months post-treatment. The trial is expected to begin in February 2025 and conclude in October 2026.

Trial Details

The study aims to investigate whether a single dose of 25 mg psilocybin can reduce the symptoms of grief and trauma associated with PGD. It is hypothesized that psilocybin will significantly reduce the symptoms of PGD and that the treatment will facilitate subjective mystical, spiritual, or insightful experiences, which in turn may contribute to the alleviation of grief and trauma symptoms.

Trial Number NCT06724289

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.